Reata Pharmaceuticals has announced that it will present Phase 2 results from a trial of its investigational therapy bardoxolone methyl in treating pulmonary arterial hypertension (PAH). The study’s findings will be presented October 27, 2015 at the 2015 American College of Chest Physicians (CHEST) annual meeting in Montreal, Canada in a…
Cytori Therapeutics recently published a report of 12-month data from the Scleradec-I clinical trial studying hand dysfunction in people with scleroderma. Findings from the 12 patient trial, which was led by Dr. Brigitte Granel and Dr. Guy Magalon of the Assistance Publique des Hôpitaux de Marseille in France, is titled “Autologous…
Launching today, the Burbank, California-based phaware global association (phaware) is a new non-profit organization and website founded by a group of pulmonary hypertension (PH) awareness advocates. The main purpose of phaware is to reach the general public, news media, and potential donors in order to…
Sunshine Heart, Inc., an early-stage medical device company focused on developing, manufacturing and commercializing the C-Pulse System for treatment of Class III and ambulatory Class IV heart failure, has announced the start of a research collaboration with Dr. Mark Slaughter and the University of Louisville to explore the technology’s potential benefits for…
A recent review, entitled “Medical treatment update on pulmonary arterial hypertension,” presents the latest research for three new drugs that have been approved by the US FDA to treat PAH. The review, which is published in Therapeutic Advances in Chronic Disease, highlights the mechanisms of action for the…
Research scientists at Bayer HealthCare AG in Germany are optimizing a new chemical inhibitor for pulmonary arterial hypertension (PAH) treatment. The team of medicinal chemists generated a library of compounds centered around inhibiting human neutrophil elastase (HNE), a key driver of inflammation in PAH. After generating molecules that successfully inhibited…
It was once thought among doctors that patients with pulmonary hypertension, many of whom can’t even walk a short distance without being short of breath, shouldn’t exercise. Pulmonary hypertension is a disease that leads to high blood pressure in the arteries of the lungs. When this occurs, the right side of the…
An 18 year-long prospective study on the length of television watching and the risk of pulmonary embolism revealed a positive correlation between the length of time a person watches television per day and the risk of developing a possibly fatal pulmonary embolism. The study was presented at the …
In a new study titled “Symptom Interference Severity and Health-Related Quality of Life in Pulmonary Arterial Hypertension,” researchers determined which symptoms experienced by people with pulmonary arterial hypertension (PAH) are most self-limiting and interfering in daily quality of life. The study was published in the…
The recent announcement of positive results for the AMBITION trial testing combinatorial ambrisentan and tadalafil in patients with pulmonary arterial hypertension (PAH) is bringing more attention to the need to actively recruit participants for clinical trials. Without patients and clinicians interested in trying new treatments for a currently…
The European Society of Cardiology (ESC) together with the European Respiratory Society (ERS) recently launched a new treatment algorithm for pulmonary arterial hypertension in its updated pulmonary hypertension guidelines. The amended protocol aims to provide patients with the best chance of a positive clinical outcome despite being diagnosed with…
Gilead Sciences, Inc. recently announced the publication of data in The New England Journal of Medicine concerning the AMBITION trial evaluating the combination therapy of Letairis® (ambrisentan) and tadalafil for pulmonary arterial hypertension (PAH). The AMBITION trial (NCT01178073) is a multicenter, randomized, double-blind…
Get regular updates to your inbox.